Technical Analysis for IMM - Immupharma Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 5.42 | 8.40% | 0.42 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical IMM trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 8.40% | |
| Lower Bollinger Band Walk | Weakness | 8.40% | |
| New 52 Week Low | Weakness | 8.40% | |
| Stochastic Reached Oversold | Weakness | 8.40% | |
| Wide Bands | Range Expansion | 8.40% | |
| Below Lower BB | Weakness | 8.40% | |
| Lower Bollinger Band Touch | Weakness | 8.40% | |
| Oversold Stochastic | Weakness | 8.40% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.37% | |
| Lower Bollinger Band Walk | Weakness | 0.37% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | about 5 hours ago |
| 5x Volume Pace | about 9 hours ago |
| 3x Volume Pace | about 9 hours ago |
| 2x Volume Pace | about 9 hours ago |
| 1.5x Volume Pace | about 9 hours ago |
Get a Trading Assistant
Immupharma Plc Description
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Medicine Clinic Cement Disease Earl Cancer Medical Specialties Diseases Drugs Mr Drug Discovery Autoimmune Diseases Disorders Infection Antibiotic Infectious Diseases Patent Infections Lupus Antibiotics Bacterial Diseases Healthcare Associated Infections Methicillin Opioids Staphylococcus Aureus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.05 |
| 52 Week Low | 4.8628 |
| Average Volume | 558,550 |
| 200-Day Moving Average | 8.22 |
| 50-Day Moving Average | 7.02 |
| 20-Day Moving Average | 6.64 |
| 10-Day Moving Average | 6.24 |
| Average True Range | 0.71 |
| ADX | 24.11 |
| +DI | 9.88 |
| -DI | 20.58 |
| Chandelier Exit (Long, 3 ATRs) | 5.36 |
| Chandelier Exit (Short, 3 ATRs) | 7.01 |
| Upper Bollinger Bands | 7.93 |
| Lower Bollinger Band | 5.36 |
| Percent B (%b) | -0.14 |
| BandWidth | 38.63 |
| MACD Line | -0.42 |
| MACD Signal Line | -0.24 |
| MACD Histogram | -0.1787 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.41 | ||||
| Resistance 3 (R3) | 6.52 | 6.16 | 6.17 | ||
| Resistance 2 (R2) | 6.16 | 5.80 | 6.10 | 6.09 | |
| Resistance 1 (R1) | 5.58 | 5.58 | 5.40 | 5.47 | 6.02 |
| Pivot Point | 5.22 | 5.22 | 5.13 | 5.17 | 5.22 |
| Support 1 (S1) | 4.64 | 4.86 | 4.46 | 4.53 | 3.98 |
| Support 2 (S2) | 4.28 | 4.64 | 4.23 | 3.91 | |
| Support 3 (S3) | 3.70 | 4.28 | 3.83 | ||
| Support 4 (S4) | 3.59 |
